コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ate in complementarity-determining region 2 (CDR2).
2 uon in complementarity-determining region 2 (CDR2).
3 their complementarity determining region 2 (CDR2).
4 r degeneration breast/ovarian cancer antigen cdr2.
5 umors that express a neuronal antigen termed cdr2.
6 C3, perhaps by affecting the conformation of CDR2.
7 alpha chain responsible for these effects is CDR2.
8 occurs in cells at cortical nodes formed by Cdr2.
9 within CDR1 and occurs with complete loss of CDR2.
10 rea (SA) due, in part, to the protein kinase Cdr2.
11 s bound endogenous CDR2L, but not endogenous CDR2.
12 sing VH1-46 Abs to Dsg3 reactivity reside in CDR2.
13 ted that Ssp1 promotes mitotic entry through Cdr2.
14 erage of 2-3% deamidation in the heavy chain CDR2, 20-25% deamidation in the Fc domain, and 10-15% N-
15 e describe that such a screen has identified cdr2(+), a gene that has an important role in the mitoti
17 recruits other CR components to nodes, pulls Cdr2 aberrantly into the CR, and reduces rates of CR mat
24 sion in a manner dependent on the SAD kinase Cdr2, advances the G2/M transition, precociously recruit
25 nthetically lethal with cdc25, nim1/cdr1, or cdr2, all of which are unable to activate the p34cdc2 ki
32 fluid and serum from PCD patients as well as CDR2 and CDR2L antibodies to neuronal tissue, cancer cel
33 kinectin (KTN1) and that double knockout of CDR2 and CDR2L enhances KTN1-dependent ER sheet stacking
34 ines, and cells transfected with recombinant CDR2 and CDR2L to elucidate which is the major antigen o
36 eptor function, whereas mutations in CD8beta CDR2 and CDR3 loops abolish CD8alphabeta coreceptor acti
37 06 with the N-terminal domain of TG2 via the CDR2 and CDR3 loops of the heavy chain and the CDR2 loop
39 ta2TCR to BTN2A1 through the regions between CDR2 and CDR3 of the TCR gamma chain and modulated by th
44 ments for particular side chains in CDR1 and CDR2 and in their relative binding contributions among d
47 am kinase and similar phosphorylation sites, Cdr2 and Ssp2 have distinct regulatory input cues and di
48 anti-Id were located in heavy chain CDR1 and CDR2 and were peripheral to the residues within the Lewi
49 C binding as a result of mutations in either CDR2 and/or CDR3 loops, that bound to the MHC or peptide
51 ing to complementarity-determining region 2 (CDR2) and CDR3 of the immunizing MBP-reactive T cell clo
52 y cerebellar degeneration-related protein 2 (CDR2) and its paralog CDR2-like (CDR2L), onconeural anti
53 utants and identified mutations in the CDR1, CDR2, and CDR3 loops that decreased binding to MHC class
55 s in complex with QL9-L(d) showed that CDR1, CDR2, and CDR3beta conformations and docking orientation
57 ing indicates not only that residues in FR1, CDR2, and FR3 are involved but also that the three regio
58 complementarity-determining region 1 (CDR1), CDR2, and framework region 3 (FR3) are predicted to be m
59 the database of canonical forms for CDR1 and CDR2, and has implications for antigen recognition by TC
60 plementarity-determining region 1 (CDR1) and CDR2, and less than two replacements in the framework re
61 e found that the mRNA levels of ERG11, CDR1, CDR2, and MDR1, the candidate fluconazole resistance gen
62 sively bearing VDJ rearrangements with CDR1, CDR2, and nearly intact DH segments in germline configur
64 key positions in the VH gene encoding CDR1, CDR2, and the immunoglobulin framework that are critical
65 om1 phosophorylated the C-terminal domain of Cdr2, and this modification reduced Cdr2-T166 phosphoryl
66 n contrast, it has been argued that CDR1 and CDR2 are involved to a greater extent than CDR3s in the
67 ged division response (Cdr) kinases Cdr1 and Cdr2 are negative regulators of Wee1, and we show that t
68 plementarity-determining regions (CDR) 1 and CDR2 are often used to bind exposed areas of the MHC alp
69 t essential for viability, but cells lacking cdr2(+) are elongated relative to wild-type cells, spend
71 regulation exerted by Pom1 on Cdr2 prevents Cdr2 assembly into stable nodes in the cell tip region w
72 del is supported by experiments showing that Cdr2 associates with the N-terminal regulatory domain of
73 In this study, we show that Pom1 modulates Cdr2 association with membranes by phosphorylation of a
75 V beta bias occurred as a consequence of the CDR2 beta loops determining the affinity of the iNKT TCR
76 1 and 2 bind one NA monomer, the light-chain CDR2 binds the neighbouring monomer, whereas HCDR3 inter
78 BV5S2 complementarity-determining region 2 (CDR2) can boost significantly the frequency of circulati
83 s of the CDR region here designated CDR1 and CDR2 (closest to the carboxyl end) each consist of about
84 complementary determining region (CDR)1 and CDR2 coincided with a combination of overlapping AGCT ho
86 g Ag recognition while gene-encoded CDR1 and CDR2 contribute to the fine specificity of the TCR-pepti
89 taining the amino acid sequences of CDR1 and CDR2 (designated bCDR1 and bCDR2) were synthesized, and
90 If the overlapping hotspots in the CDR1 or CDR2 did not undergo mutation, the frequency of mutation
91 e septation initiation network (SIN) induces Cdr2 dissociation from cytokinetic precursors at this st
93 ty-determining regions (CDRs), with CDR1 and CDR2 encoded by the V segment and CDR3 encoded by the V(
95 are independent of wee1(+), suggesting that cdr2(+) encodes a second activity involved in cytokinesi
96 ed and implies that residues in the CDR1 and CDR2-equivalent loops of CD8beta are occluded upon bindi
100 ssion system, we found that a 6x increase in Cdr2 expression caused hyperphosphorylation of Wee1 and
101 of 9 of these events occurred in the CDR1 or CDR2, following a pattern consistent with selection, and
103 TLs) specific for the PCD onconeural antigen cdr2 found in the blood of patients with PCD are likely
104 he monoclonal immunoglobulin light chain FR2-CDR2-FR3 was sequenced by database-aided de novo MS/MS a
106 nd suggest a mechanism whereby inhibition of cdr2 function by autoantibodies in PCD may contribute to
110 mutants carrying one to five mutations in VH CDR2 had reduced or abolished Ag binding, while 10% were
113 al pool demonstrates more Pom1 overlaps with Cdr2 in short than long cells, consistent with Pom1 inhi
114 , Asp54 isomerization and Met56 oxidation in CDR2 in the heavy chain of mAb1 result in opposing confo
115 e second complementarity-determining region (CDR2) in the light chain, is due to a spatial proximity
116 ea sensing and supporting the existence of a Cdr2-independent secondary sizer mechanism more closely
120 -privileged sites, the expression pattern of cdr2 is compatible with the autoimmune model of PCD path
121 determine whether the expression pattern of cdr2 is consistent with its proposed role in PCD, we hav
122 ly specified by cell volume, suggesting that Cdr2 is essential for area sensing and supporting the ex
123 ly expressed in such tumors, indicating that cdr2 is in fact an important tumor antigen in the genera
125 activation of the conserved mitotic inducer Cdr2 is integrated with an inhibitory spatial gradient t
126 lear, due in part to reports indicating that cdr2 is not expressed in tumors obtained from neurologic
127 We demonstrate in human cancer cells that CDR2 is recruited by the integral ER membrane protein ki
130 e reexamined this question, and we find that cdr2 is widely expressed in such tumors, indicating that
132 the V region, and especially of the CDR1 and CDR2, is highly evolved to recruit mutations to key resi
136 lls divide at a threshold size partly due to Cdr2 kinase, which forms nodes at the medial cell cortex
138 and eEF1Bbeta knockdown increases endogenous CDR2 levels on ER sheets, inducing their centrosome-prox
139 ion-related protein 2 (CDR2) and its paralog CDR2-like (CDR2L), onconeural antigens with poorly under
143 this hotspot, key germline-encoded CDR1 and CDR2 loop residues and a crucial but commonly coded resi
144 eptibility to papain cleavage in an adjacent CDR2 loop, and the tendency of the newly formed isoAsp t
145 ts of the CD8alpha CDR2 and CD8beta CDR1 and CDR2 loops as well as the flexibility of the H-2D(d) CD
149 consistent with the notion that the CDR1 and CDR2 loops of the TCR are responsible for MHC restrictio
150 ionarily selected germline Valpha/Vbeta CDR1/CDR2 loops to create highly MHC/peptide cross-reactive T
151 igh amino acid diversity of the TCR CDR1 and CDR2 loops, and that such conservation is unlikely to do
155 between cell polarity proteins and the Cdr1-Cdr2 module might underlie the coordination of cell grow
162 of this property, upon nitrogen deprivation cdr2(+) mutants do not arrest in G1, but rather undergo
163 the Vbeta8.2-SEC3 complex suggests that the CDR2 mutations act by disrupting Vbeta main chain intera
164 Their GC progeny were rapidly selected for CDR2 mutations that blocked 72% of antigen-binding sites
166 sidue (Thr166) in the activation loop of the Cdr2 N-terminal kinase domain both in vitro and in cells
174 Our work identifies a regulated anchor for Cdr2 nodes that is required for cells to sense surface a
178 hat when the anti-dextran V(H) CDR2 replaced CDR2 of an anti-dansyl V(H), the glycosylation site was
180 restored full viral receptor activity to the CDR2 of human CD134 in the context of feline CD134, with
182 he epitope was recognized mainly by CDR1 and CDR2 of the heavy chain, which are highly conserved amon
185 lored the sequence requirements for CDR1 and CDR2 of the TCR alpha-chain in a human T cell response c
187 rate that single amino acid substitutions in CDR2 of the TCR-alpha chain controlled whether a T cell
188 Mutational analysis of residues in CDR1 and CDR2 of the three Valpha2 regions showed the importance
189 plementarity determining region 1 (CDR1) and CDR2 of the V alpha element can be responsible for deter
190 The complementarity-determining region 2 (CDR2) of the beta-chain and, to lesser extents, CDR1 and
191 ite in the complementary determining region (CDR2) of the heavy chain variable region were elucidated
192 chain complementarity determining region 2 (CDR2) of the phosphocholine-specific T15 Ab can have a d
193 d that complementarity determining region 2 (CDR2) of the Vbeta contributed the majority of binding e
194 in the complementarity-determining region 2 (CDR2) of the VH, and the presence of carbohydrate leads
195 omplementarity determining regions (CDR1 and CDR2) of this Valpha are shorter than the CDRs correspon
198 en another carbohydrate was present in CDR1, CDR2, or CDR3 of the L chain, the V(H) CDR2 glycan remai
202 ce of a cka2 mutant, as expected if CDR1 and CDR2 overexpression is responsible for fluconazole resis
205 l involve a limited set of slightly modified CDR2 peptides from BV genes involved in T cell recogniti
206 S2 peptides were immunized successfully with CDR2 peptides from different BV gene families overexpres
207 east one of three overlapping or substituted CDR2 peptides possessing a core epitope of residues 44-5
210 that the dual regulation exerted by Pom1 on Cdr2 prevents Cdr2 assembly into stable nodes in the cel
212 w here that SIN-dependent phosphorylation of Cdr2 promotes its interaction with the 14-3-3 protein Ra
213 chizosaccharomyces pombe, the protein kinase Cdr2 promotes mitotic entry by organizing cortical oligo
214 ever, Yo antibodies can bind the recombinant CDR2 protein used in routine clinical testing for these
215 n was blocked by heavy chain residues in the CDR2 region and appeared to lack part of the canyon wall
218 ite, amino acid residue Asn55 located in the CDR2 region of the heavy chain, is of particular interes
219 t recognize a TCR peptide from the conserved CDR2 region of the TCR Vbeta8.2-chain in the context of
220 y occurring somatic mutations in the H chain CDR2 region that conferred a markedly prolonged off-rate
224 is study shows that residues in the CDR1 and CDR2 regions are primary determinants for MHC class disc
225 eptides, and moderately diverse TCR CDR1 and CDR2 regions contact moderately diverse MHC alpha-helice
226 ouse Vbeta8 family, has amino acids in their CDR2 regions that consistently bind a particular site on
228 ly, we found that when the anti-dextran V(H) CDR2 replaced CDR2 of an anti-dansyl V(H), the glycosyla
236 te in the first 6 weeks have unique CDR1 and CDR2 sequences, permitting each to be identified using s
237 n II/III V(H)s share more positively charged CDR2 sequences, whereas high IF clan I J558 CDR2 sequenc
241 These mice were used to clone high-avidity cdr2-specific CD8(+) T cells that recognize human tumor
242 panded populations of MHC class I-restricted cdr2-specific CTLs in the blood of 3/3 HLA-A2.1+ PCD pat
244 rolimus also reduced the number of activated cdr2-specific CTLs in the peripheral blood, but did not
247 ic and contained cryptic determinants as the CDR2-specific T cell lines did not recognize autologous
248 ell receptor (TCR) alpha and beta genes from cdr2-specific T cells; electroporation of RNA encoding t
254 cdr2 mutant in an Ssp1 phosphorylation site (cdr2-T166A) [4] should form nodes whose density register
258 body response to the tumor and brain antigen cdr2, this humoral response has not been shown to be pat
260 ring precursors organized by the SAD kinase Cdr2 to pre-define the division plane [5-8]; then, massi
266 mplementarity-determining region 1 (CDR1) or CDR2 were sufficient to change selection from the CD4 su
267 ncentrations of either kinase Pom1 or kinase Cdr2 were varied with the nmt1 promoter, the numbers of
269 plementarity-determining region 1 (CDR1) and CDR2, which exhibited higher replacement-to-silent ratio
270 ls the timing of mitotic entry by inhibiting Cdr2, which forms stable membrane-associated nodes at mi
272 to the conserved cell cycle kinases Cdr1 and Cdr2, which localize to a set of cortical nodes in the c
273 tumors express an onconeural antigen termed cdr2, which normally is expressed in cerebellar Purkinje
274 on in fission yeast is the SAD family kinase Cdr2, which organizes a set of cortical nodes in the cel
275 D-induced mutations primarily in the AGCT in CDR2, which was also the most frequent site of mutation
276 placing the overlapping hotspots in CDR1 and CDR2 with neutral or cold motifs resulted in a reduction